Stock Insights : DLF Ltd, Lloyds Enterprises Ltd, Zydus Lifesciences Ltd, RITES Ltd, Kamat Hotels Ltd - ARETE Securities Ltd

Market Updates
The markets are expected to open marginally lower today as trends in GIFT NIFTY indicate a negative start for the broader index after NIFTY closed 205 points lower at 25,149 on Friday.
DLF
The company received Rs.100 crore as first tranche under arbitration settlement with TFDRL and remaining amount is secured via 1.5 lakh sq ft mortgage.
HFCL
The company approved Rs.125.55 crore capex to expand IBR cable capacity from 1.73 mfkm to 19.01 mfkm across Hyderabad and Goa by June 2026.
HUDCO
The company signed a non-binding MoU with MPUDCL to provide Rs.1,00,000 crore financial assistance over 5 years for housing and infrastructure projects.
Kamat Hotels
The company signed an agreement to manage a second luxury hotel in Rishikesh with 44 rooms under The Orchid brand.
Lloyds Enterprises
The company’s subsidiary LRDL signed an MOU to acquire 51% in CLPL for ?60 crore and extend Rs.242 crore debt to develop 99-acre Taloja logistics park.
NCC
The company received Rs.2,269 crore LOA from MMRDA for a 24-month Mumbai Metro Line 6 Package-1 project including signalling, telecom, and rolling stock.
RITES
The company received Rs.46.82 crore turnkey order (36-month duration) from DCTE Karnataka for college construction and renovation under PM-USHA scheme.
RVNL
The company received Rs.213.22 crore LOA from South Central Railway for 24-month OHE upgradation in Duvvada–Rajahmundry & Samalkot–Kakinada Port section.
Tata Elxsi
The company signed a MoU with Synopsys to jointly offer advanced vECU and digital twin solutions for software-defined vehicle development and validation.
Titagarh Rail Systems
The company signed a 99-year lease with WB Govt for 40.009 acres at Rs.126.63 crore to expand metro, Vande Bharat and defence rolling stock infra with testing and commissioning facilities at Uttarpara.
Wockhardt
The company exited the US generics segment after $8 million FY25 loss, filing Chapter 7 for 2 US units to focus on antibiotics and insulin.
Zydus Lifesciences
The company’s US subsidiary ZPUI incorporated Zylidac Bio LLC in the US to acquire biologics manufacturing assets of Agenus.
Please refer disclaimer at http://www.aretesecurities.com/
SEBI Regn. No.: INM0000127










Tag News

MOSt Market Roundup :Nifty opened flat but slid steadily through most of the session by Mot...


